Second Line Chemotherapy for Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
No validated second-line chemotherapy for the treatment of locally advanced/metastatic
pancreatic cancer is actually available,after the failure of a gemcitabine(+/- Cisplatin or
Oxaliplatin)-based regimen.
Irinotecan seems to be a moderately active drug in the treatment of this disease Recently was
reported some interesting results using a potentially non -cross resistant regimen (FOLFIRI)
which could be useful even as second-line chemotherapy.
An exploratory study in this setting seem warranted.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer